Clinical Trial Update: A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of ESG206 in patients with primary immune thrombocytopenia is currently recruiting. The trial aims to evaluate safety and preliminary efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• ESG206

Snippet

Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Conditions: Immune Thrombocytopenia (ITP) | Phase 1, Phase 2 | Status: RECRUITING